Diffuse, non-inflammatory, non-neoplastic enlargement of the major salivary glands (sialosis) is uncommon and has various systemic causes. This paper examines 35 patients whose persistent swelling of the parotid was diagnosed as sialosis, and shows that diabetes mellitus and alcoholism are the most common causes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bjoms.2008.01.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.
Front Pharmacol
October 2024
Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kraków, Poland.
Aim: Our objective was to systematically assess the prevalence and clinical features of adverse events related to interactions between cannabinoids and psychotropic drugs through a retrospective chart review.
Methodology: 1586 adverse event reports were assessed. Cases included in the analysis showed a high probability of a causal relationships between cannabinoid-psychotropic drug interactions and adverse events.
Staggered botulinum toxin-a injections into parotid and submandibular glands prior to four-duct ligation for pediatric sialorrhea.
Eur Arch Otorhinolaryngol
October 2024
Department of Otorhinolaryngology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Objectives: This study aimed to assess the effectiveness of four-duct ligation following Botulinum toxin-A injections into the parotid and submandibular glands in pediatric patients with sialorrhea resistant to nonsurgical treatments. Prior research has individually explored either surgical or Botulinum toxin interventions; however, the safety and efficacy of the combined approach to these treatments have yet to be documented.
Methods: Patients were assessed before surgery and 6, 12, and 24 months post-operatively.
Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis.
J Neurol
October 2024
Department of Neurology, Hannover Medical School, 1, Carl-Neuberg-Strasse, 30625, Hannover, Germany.
The degenerative motor neuron disorder amyotrophic lateral sclerosis (ALS) frequently leads bulbar symptoms like dysarthria, dysphagia, and sialorrhea, in approximately one-third of cases being the initial symptom. Throughout the disease, more than two-thirds of ALS patients experience dysphagia, regardless of the region of onset. In this review, we aimed to offer an updated overview of dysphagia and sialorrhea in ALS, covering its diagnosis, monitoring, and treatment in clinical practice.
View Article and Find Full Text PDFNavigating the spectrum of pediatric sialorrhea management: A narrative review.
Am J Otolaryngol
August 2024
Department of Otolaryngology - Head and Neck Surgery, Division of Pediatric Otolaryngology, University of Florida College of Medicine, Gainesville, FL, USA.
Objective: This review summarizes the approaches to pediatric sialorrhea management from least-to-most invasive: non-pharmacological management, anticholinergic medications, botulinum neurotoxin, non-invasive surgery, and invasive surgical intervention.
Review Methods: An electronic literature review identified English-language articles on sialorrhea management in pediatric patients. Publications between 1982 and 2022 were used, with a focus on articles published from 2012 to 2022.
The when, why, and how of using glycopyrronium to diminish drooling in children with neurodevelopmental disabilities: Implications for clinical practice.
Eur J Paediatr Neurol
July 2024
Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital, Department of Paediatric Neurology, Division of Paediatrics, Nijmegen, the Netherlands.
Background: Despite the established efficacy of glycopyrronium bromide in reducing drooling among children with neurodevelopmental disabilities, evidence on its impact on the daily lives of children and parents and effectiveness in a real-world setting are scarce, especially among long-term users. This study explored timing and duration of glycopyrronium treatment, effect and impact on daily life, and occurrence of side effects to inform clinical practice.
Methods: This was a retrospective cohort study at a national referral centre for drooling, including 61 children with nonprogressive neurodevelopmental disabilities, treated with glycopyrronium for anterior and/or posterior drooling between 2011 and 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!